Successful treatment of concomitant metastatic prostate cancer and B-cell non-Hodgkin’s lymphoma with R-EPOCH chemotherapy regimen and antiandrogen therapy

Hanna, Fayez; Prakash, Ajay; Allan, Ebony; Khalafallah, Alhossain A

doi:10.1136/bcr-2017-223637

Cited by 5 publications

(4 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is still no standard approach regarding the treatment regimen to be followed for cases with renal involvement. However, successful cases of treatment with the DA-EPOCH-R regimen have been reported in the literature [26,27]. In conclusion, renal involvement in DLBCL is rare, however, it is associated with poor prognosis.…”

Section: Discussionmentioning

confidence: 93%

Renal involvement in diffuse large B-cell lymphoma: A case report

Demi̇rci̇oğlu¹,

Telci²,

Özçelik³

et al. 2019

Marmara Medical Journal

View full text Add to dashboard Cite

Diffuse large B-cell lymphoma is the most common subtype of non-Hodgkin lymphoma. Approximately 40% of cases have extranodal involvement. Renal involvement is rare, however, it is associated with poor prognosis. Furthermore, renal involvement increases the risk of central nervous system (CNS) recurrence. Therefore, it is recommended that CNS prophylaxis should be included in lymphoma treatment in cases of renal involvement.

show abstract

Section: Discussionmentioning

confidence: 93%

Renal involvement in diffuse large B-cell lymphoma: A case report

Demi̇rci̇oğlu¹,

Telci²,

Özçelik³

et al. 2019

Marmara Medical Journal

View full text Add to dashboard Cite

show abstract

“…Recently, de Souza et al pointed out that lymphoma may present as PSMA uptake after reviewing the data of 10 patients with different histological subtypes of lymphomas, and they subsequently found that the intensity of PSMA uptake was generally lower than FDG ( 11 ). Furthermore, several published case reports have also found that the PSMA expression of lymphoma was extremely low, or even had no expression ( 12 – 14 ). Thus, we deemed that the expression of PSMA on lymphoma was lower than adenocarcinoma, while the expression of FDG was higher.…”

Section: Discussionmentioning

confidence: 99%

18F-Prostate-Specific Membrane Antigen and 18F-Fluorodeoxyglucose PET/CT Unmasked the Characteristics of Prostate Lymphoma: A Case Report and Literature Review

Fan

Liang

et al. 2022

Front. Med.

View full text Add to dashboard Cite

Prostate lymphoma (PL) is rarely observed and may be concurrently presented with prostate adenocarcinoma. Moreover, the appearance of PL on conventional imaging is similar with prostate adenocarcinoma. Thus, most of PL is diagnosed through prostate biopsy, or accidentally found in the specimens of surgery. Prostate-specific membrane antigen (PSMA) PET/CT has improved the management of prostate adenocarcinoma. While, the question regarding whether it benefits the discovery of the characteristics of PL is unknown. A 32-year-old man presented with worsening dysuria for 1 month, and the prostate-specific antigen (PSA) concentration was normal. While the pelvic MRI showed a mass in the prostate and multiple enlarged lymph nodes in the bilateral inguinal area. Then, the diagnosis of prostate adenocarcinoma was considered, but the serum PSA was normal and he was younger than most patients. So, 18F-PSMA PET/CT was then performed to further reveal the characteristics of the lesion and guide biopsy. However, there was no abnormal PSMA uptake in the lesion of the prostate and lymph nodes of the pelvic cavity and bilateral inguinal area. These lesions presented with increased glucose metabolism on fluorodeoxyglucose (FDG) PET/CT, and the prostate biopsy was then performed. PL was confirmed based on the results of the histopathologic examination, and the patient subsequently received systemic chemotherapy plus radiotherapy. Fortunately, the symptoms and the lesions completely disappeared after radiotherapy. The clinical symptoms of PL are atypical, and PL and adenocarcinoma may be concurrently presented. Moreover, distinguishing PL from prostate adenocarcinoma based on the appearance of conventional imaging is difficult. As opposed to prostate adenocarcinoma, a high FDG-avidity and low PSMA uptake by lymphoma either in the prostate or metastases are seen. So, PSMA PET/CT combined with FDG PET/CT can non-invasively identify the characteristics and origin of PL.

show abstract

“…In univariate analysis, we found that the dose of etoposide may affect the occurrence of neutropenia, but further inclusion in multivariate analysis revealed a nonsignificant effect on neutropenia. It is possible that although this study involved chemotherapy for multiple tumors, the dose distribution of etoposide was relatively concentrated regardless of the chemotherapy regimen [34][35][36]. Among the variables used to develop the nomogram in this study, KPS, comorbidity with heart disease, recent surgery, administration of alkylating agents, TBil ≥25 umol/L, and lymphocytes <0.7 × 10 9 /L have also been used in previous studies [5,8,9,18,37,38].…”

Section: Discussionmentioning

confidence: 99%

A Risk-Prediction Nomogram for Neutropenia or Febrile Neutropenia after Etoposide-Based Chemotherapy in Cancer Patients: A Retrospective Cohort Study

Zhu¹,

Guo²,

Kong

et al. 2021

Pharmacology

View full text Add to dashboard Cite

Introduction: This study was conducted to develop and validate a nomogram for predicting the risk of neutropenia or febrile neutropenia (FN) in tumor patients in the first cycle of etoposide-based chemotherapy. Methods: This retrospective cohort study used an information system to monitor patients with non-Hodgkin’s lymphoma or solid tumors receiving an etoposide regimen in the first chemotherapy cycle in our hospital from 2009 to 2020. Binary logistic regression analysis was used to identify the influencing factors of patients with neutropenia or FN. Those factors were then used to develop a nomogram. Results: A total of 1,554 patients were divided into the development group (n = 1,072) and validation group (n = 482). Variables used to predict neutropenia or FN were Karnofsky performance status (odds ratio [OR] = 0.85, 95% confidence interval [CI] = 0.81–0.89, p < 0.01), metastatic sites ≥3 (OR = 6.33, 95% CI = 2.66–15.11, p < 0.01), comorbidity of heart disease (OR = 4.88, 95% CI = 1.74–13.67, p < 0.01), recent surgery (OR = 7.96, 95% CI = 1.96–32.36, p < 0.01), administration of alkylating agents (OR = 4.50, 95% CI = 1.10–18.48, p < 0.01), total bilirubin ≥25 μmol/L (OR = 11.42, 95% CI = 4.00–32.61, p < 0.01), and lymphocyte count <0.7 × 109/L (OR = 4.22, 95% CI = 2.00–9.75, p < 0.01). Conclusion: This model can aid the early identification and screening of the potential risk of neutropenia or FN in the first cycle of treatment for patients using etoposide-based chemotherapy.

show abstract

Successful treatment of concomitant metastatic prostate cancer and B-cell non-Hodgkin’s lymphoma with R-EPOCH chemotherapy regimen and antiandrogen therapy

Cited by 5 publications

References 21 publications

Renal involvement in diffuse large B-cell lymphoma: A case report

Renal involvement in diffuse large B-cell lymphoma: A case report

18F-Prostate-Specific Membrane Antigen and 18F-Fluorodeoxyglucose PET/CT Unmasked the Characteristics of Prostate Lymphoma: A Case Report and Literature Review

A Risk-Prediction Nomogram for Neutropenia or Febrile Neutropenia after Etoposide-Based Chemotherapy in Cancer Patients: A Retrospective Cohort Study

Contact Info

Product

Resources

About